Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Status unconfirmed · Phase 2

Conditions studied: Malignant Melanoma, Neoplasm Metastasis

In brief

This is a research study to look at the ways in which a treatment called INGN241 can kill melanoma cells or help the patient's immune system kill melanoma cells.

Key facts

Study ID

NCT00116363

Run by

Introgen Therapeutics

People needed

25

Starts

2005-03-01

Expected to finish

2006-12-01

Last updated by the study team

2008-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven melanoma, must have 3 regional metastatic lesions that are in transit

You may not qualify if…

• Central nervous system involvement by melanoma

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.